Glutamine

Glutamine

SCHEMBL432398

CC(N)C(=O)O.NC(=O)CCC(N)C(=O)O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.83
PMP22 Q01453 2/20 0.83
ALOX15 P16050 1/20 0.83
BLM P54132 1/20 0.83
CYP1A2 P05177 3/20 0.58
GSR P00390 2/20 0.58
SLC1A3 P43003 2/20 0.58
SLC1A2 P43004 2/20 0.58
SLC1A1 P43005 2/20 0.58
GRM8 O00222 1/20 0.58
GRM6 O15303 1/20 0.58
GRIN2D O15399 1/20 0.58
GRIN3B O60391 1/20 0.58
GRIK1 P39086 1/20 0.58
GRM5 P41594 1/20 0.58
GRIA1 P42261 1/20 0.58
GRIA2 P42262 1/20 0.58
GRIA3 P42263 1/20 0.58
GRIA4 P48058 1/20 0.58
GRIN1 Q05586 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamine SCHEMBL6555864 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL3688684 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL5848376 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL104313 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL3059857 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL14485584 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL4613452 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL5085797 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL20553625 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL11170132 1.00 KMT2A (0.83) KMT2APMP22ALOX15BLMCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119265134-A System, method and organoid suitable for organ/organoid circulatory culture 苏州先觉生物科技有限公司 2025-01-07 CN claimed
US-10557854-B2 CA IX—NIR dyes and their uses On Target Laboratories, LLC (US) 2020-02-11 US claimed
EP-0906333-B1 SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES MEDIVIR UK LTD (GB) 2001-07-25 EP claimed
CN-119265134-A System, method and organoid suitable for organ/organoid circulatory culture 苏州先觉生物科技有限公司 2025-01-07 CN disclosed
US-20240261363-A1 METHODS OF TREATING AND PREVENTING CANCER TREATMENT SIDE EFFECTS FILAMENT BIOSOLUTIONS INC. 2024-08-08 US disclosed
US-11987633-B2 Cross-species-specific single domain bispecific single chain antibody AMGEN RESEARCH (MUNICH) GMBH (DE) 2024-05-21 US disclosed
CN-117357626-A Peritoneal dialysis fluid 杰拓保护有限公司 2024-01-09 CN disclosed
CN-114345825-B Mask cleaning method, cleaning liquid, cleaning apparatus, and method for manufacturing organic device 大日本印刷株式会社 2023-08-22 CN disclosed
US-20230250406-A1 MUTANT LIPASE AND USE THEREOF DSM IP ASSETS B.V. (NL) 2023-08-10 US disclosed
EP-3538065-B1 COSMETIC FORMULATIONS FOR TOPICAL APPLICATIONS CONTAINING ERYTHROPOIETIN-DERIVED MOLECULES ASC REGENITY LTD (GB) 2023-08-02 EP disclosed
EP-4180458-A1 CROSS-SPECIES-SPECIFIC PSMA X CD3 BISPECIFIC SINGLE CHAIN ANTIBODY Amgen Research (Munich) GmbH (DE) 2023-05-17 EP disclosed
EP-2038417-A2 COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF IL-2 MEDIATED IMMUNE RESPONSES Merck Patent GmbH (DE) 2009-03-25 EP disclosed
WO-2008119566-A2 CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS MICROMET AG (DE) 2008-10-09 WO disclosed
WO-2008119565-A2 CROSS-SPECIES-SPECIFIC BINDING DOMAIN MICROMET AG (DE) 2008-10-09 WO disclosed
WO-2008119567-A2 CROSS-SPECIES-SPECIFIC CD3-EPSILON BINDING DOMAIN MICROMET AG (DE) 2008-10-09 WO disclosed
US-20080025947-A1 Methods for enhancing the efficacy of IL-2 mediated immune responses MERCK PATENT GMBH (DE) 2008-01-31 US disclosed
WO-2008003473-A2 COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF IL-2 MEDIATED IMMUNE RESPONSES MERCK PATENT GMBH (DE) 2008-01-10 WO disclosed
EP-1437966-A4 MEASUREMENT OF PROTEIN SYNTHESIS RATES IN HUMANS AND EXPERIMENTAL SYSTEMS BY USE OF ISOTOPICALLY LABELED WATER UNIV CALIFORNIA (US) 2006-08-23 EP disclosed
EP-1437966-A1 MEASUREMENT OF PROTEIN SYNTHESIS RATES IN HUMANS AND EXPERIMENTAL SYSTEMS BY USE OF ISOTOPICALLY LABELED WATER The Regents of the University of California (US) 2004-07-21 EP disclosed
WO-2003061479-A1 MEASUREMENT OF PROTEIN SYNTHESIS RATES IN HUMANS AND EXPERIMENTAL SYSTEMS BY USE OF ISOTOPICALLY LABELED WATER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10557854-B2 CA IX—NIR dyes and their uses CA9, CA13, CA4 KMT2A 3624/4885PMP22 4778/4885ALOX15 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.